Behind the Study: Extending Survival in Glioma Models
May 11, 2021
Dr. Gregory Riggins from Johns Hopkins University discusses his 2017 study published by Oncotarget, entitled, "Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients." continue reading »